Novartis NVS announced positive results from a phase III trial, FLAME, on Ultibro Breezhaler. The head-to-head trial examined the rate of chronic obstructive pulmonary disease (COPD) exacerbations.

Ultibro ® Breezhaler ® reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide ® in new analyses from FLAME study Analyses show that Ultibro Breezhaler lowered patients` ...

TOKYO and LONDON, Nov. 28, 2019 /PRNewswire/ -- Sosei Group Corporation ("the Company";) (TSE: 4565) announces that Ultibro® Breezhaler® (an inhaled once-daily ...

TOKYO--(BUSINESS WIRE)--Sosei Group Corporation (“Sosei”)(TOKYO:4565) confirms that Novartis Pharma K.K. launched once-daily Ultibro ® Inhalation Capsules (“Ultibro ® ”; glycopyrronium / indacaterol), ...

Novartis' Ultibro competes against fellow LAMA/LABA drugs Anoro, Spiolto and Duaklir in Europe. (Novartis) () The COPD market is growing more and more competitive in Europe. So Novartis is looking to ...

Treatment with Novartis’ Ultibro Breezhaler significantly boosted lung and cardiac function in chronic obstructive pulmonary disease (COPD) patients with lung hyperinflation, trial findings show.

Novartis has presented data showing that its chronic obstructive pulmonary disease drug Ultibro was superior in reducing flare-ups compared to GlaxoSmithKline’s blockbuster Seretide. Novartis has ...

Novartis data at ERS 2014 show once-daily Ultibro® Breezhaler® is superior in reducing COPD flare ups compared to Seretide® Once-daily Ultibro® Breezhaler® reduced exacerbations (flare ups) by 31% ...

The FINANCIAL — Novartis on December 8 announced positive results from the first large-scale study exploring the effects of directly switching symptomatic, non-frequently exacerbating patients with ...

QUANTIFY study met primary endpoint demonstrating non-inferiority of Ultibro®Breezhaler® vs tiotropium 18 mcg plus formoterol 12 mcg in improving health-related quality of life outcomes[1],[2] ...

Preventing exacerbations is one of the primary goals of long-term care for COPD patients. These episodes have a detrimental effect on quality of life and disease progression[2], contributing to ...

A new study suggests COPD patients experience improved lung function and breathlessness after direct switch from long-acting bronchodilators or steroid containing combination therapies to Novartis’ ...